Control of arthritis pain with anti-nerve-growth factor

Risk and benefit

Matthias F. Seidel, Nancy E Lane

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Arthritis is characterized by pain and inflammation. Recently, attention has been focused on nervegrowth factor (NGF), a neurotrophin that is a key regulator of peripheral nociception because it mediates overexpression of proinflammatory neuron-derived molecules such as substance P, serotonin, and calcitonin generelated peptide. Antibodies have been generated for NGF and its receptor that are effective in reducing pain in preclinical pain models, and clinical trials in patients with advanced knee and hip osteoarthritis and low-back pain. Results show pain reduction is rapid and sustained. Adverse events with anti-NGF included transient paraesthesia and edema, rapidly progressive OA, and, in a small number of patients treated with both anti-NGF and nonsteroidal anti-inflammatory drugs, osteonecrosis. Inhibition of the NGF-stimulated nociceptive pathway seems to be effective; however, the adverse effects require further investigation.

Original languageEnglish (US)
Pages (from-to)583-588
Number of pages6
JournalCurrent Rheumatology Reports
Volume14
Issue number6
DOIs
StatePublished - Dec 2012

Fingerprint

Nerve Growth Factor
Arthritis
Pain
Hip Osteoarthritis
Nociception
Osteonecrosis
Paresthesia
Knee Osteoarthritis
Nerve Growth Factors
Calcitonin
Substance P
Low Back Pain
Edema
Serotonin
Anti-Inflammatory Agents
Clinical Trials
Inflammation
Neurons
Peptides
Antibodies

Keywords

  • Antagonists
  • Arthritis
  • Benefit
  • Nerve-growth factor
  • Neurogenic inflammation
  • NGF
  • Pain
  • Receptor antagonists
  • Rheumaticdiseases
  • Risk

ASJC Scopus subject areas

  • Rheumatology

Cite this

Control of arthritis pain with anti-nerve-growth factor : Risk and benefit. / Seidel, Matthias F.; Lane, Nancy E.

In: Current Rheumatology Reports, Vol. 14, No. 6, 12.2012, p. 583-588.

Research output: Contribution to journalArticle

@article{01286ca47d2e45f28407c8bc60bb970d,
title = "Control of arthritis pain with anti-nerve-growth factor: Risk and benefit",
abstract = "Arthritis is characterized by pain and inflammation. Recently, attention has been focused on nervegrowth factor (NGF), a neurotrophin that is a key regulator of peripheral nociception because it mediates overexpression of proinflammatory neuron-derived molecules such as substance P, serotonin, and calcitonin generelated peptide. Antibodies have been generated for NGF and its receptor that are effective in reducing pain in preclinical pain models, and clinical trials in patients with advanced knee and hip osteoarthritis and low-back pain. Results show pain reduction is rapid and sustained. Adverse events with anti-NGF included transient paraesthesia and edema, rapidly progressive OA, and, in a small number of patients treated with both anti-NGF and nonsteroidal anti-inflammatory drugs, osteonecrosis. Inhibition of the NGF-stimulated nociceptive pathway seems to be effective; however, the adverse effects require further investigation.",
keywords = "Antagonists, Arthritis, Benefit, Nerve-growth factor, Neurogenic inflammation, NGF, Pain, Receptor antagonists, Rheumaticdiseases, Risk",
author = "Seidel, {Matthias F.} and Lane, {Nancy E}",
year = "2012",
month = "12",
doi = "10.1007/s11926-012-0289-8",
language = "English (US)",
volume = "14",
pages = "583--588",
journal = "Current Rheumatology Reports",
issn = "1523-3774",
publisher = "Current Science, Inc.",
number = "6",

}

TY - JOUR

T1 - Control of arthritis pain with anti-nerve-growth factor

T2 - Risk and benefit

AU - Seidel, Matthias F.

AU - Lane, Nancy E

PY - 2012/12

Y1 - 2012/12

N2 - Arthritis is characterized by pain and inflammation. Recently, attention has been focused on nervegrowth factor (NGF), a neurotrophin that is a key regulator of peripheral nociception because it mediates overexpression of proinflammatory neuron-derived molecules such as substance P, serotonin, and calcitonin generelated peptide. Antibodies have been generated for NGF and its receptor that are effective in reducing pain in preclinical pain models, and clinical trials in patients with advanced knee and hip osteoarthritis and low-back pain. Results show pain reduction is rapid and sustained. Adverse events with anti-NGF included transient paraesthesia and edema, rapidly progressive OA, and, in a small number of patients treated with both anti-NGF and nonsteroidal anti-inflammatory drugs, osteonecrosis. Inhibition of the NGF-stimulated nociceptive pathway seems to be effective; however, the adverse effects require further investigation.

AB - Arthritis is characterized by pain and inflammation. Recently, attention has been focused on nervegrowth factor (NGF), a neurotrophin that is a key regulator of peripheral nociception because it mediates overexpression of proinflammatory neuron-derived molecules such as substance P, serotonin, and calcitonin generelated peptide. Antibodies have been generated for NGF and its receptor that are effective in reducing pain in preclinical pain models, and clinical trials in patients with advanced knee and hip osteoarthritis and low-back pain. Results show pain reduction is rapid and sustained. Adverse events with anti-NGF included transient paraesthesia and edema, rapidly progressive OA, and, in a small number of patients treated with both anti-NGF and nonsteroidal anti-inflammatory drugs, osteonecrosis. Inhibition of the NGF-stimulated nociceptive pathway seems to be effective; however, the adverse effects require further investigation.

KW - Antagonists

KW - Arthritis

KW - Benefit

KW - Nerve-growth factor

KW - Neurogenic inflammation

KW - NGF

KW - Pain

KW - Receptor antagonists

KW - Rheumaticdiseases

KW - Risk

UR - http://www.scopus.com/inward/record.url?scp=84869186227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869186227&partnerID=8YFLogxK

U2 - 10.1007/s11926-012-0289-8

DO - 10.1007/s11926-012-0289-8

M3 - Article

VL - 14

SP - 583

EP - 588

JO - Current Rheumatology Reports

JF - Current Rheumatology Reports

SN - 1523-3774

IS - 6

ER -